The fungal genus Pyrenochaetopsis has received particular attention because of its different lifestyles, such as numerous plant pathogenic, saprophytic, and endophytic species. Its ability to infect plant cells relies heavily upon secreted peptidases. Here, we investigated the biochemical properties and catalytic specificity of a new serine peptidase secreted by the filamentous fungus Pyrenochaetopsis sp. We found that while this neutral serine peptidase displayed optimal activity at a pH of 7.0 and temperature of 45 °C, it tolerated a wide range of pH conditions and temperatures lower than 45 °C. Its peptidase activity was depressed by some metallic ions (such as aluminum, cobalt, and copper (II) chloride) and enhanced by others (such as sodium, lithium, magnesium, potassium, calcium, and manganese). Lastly, the enzyme showed the greatest specificity for non-polar amino acids, particularly leucine and isoleucine, and moderate specificity for basic and neutral polar amino acids. It displayed the least specificity for acidic residues.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s12010-018-2875-3 | DOI Listing |
JAMA Netw Open
January 2025
Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles.
Importance: The phase 3 randomized EMBARK trial evaluated enzalutamide with or without leuprolide in high-risk nonmetastatic hormone-sensitive prostate cancer. Eligibility relied on conventional imaging, which underdetects metastatic disease compared with prostate-specific membrane antigen-positron emission tomography (PSMA-PET).
Objective: To describe the staging information obtained by PSMA-PET/computed tomography (PSMA-PET/CT) in a patient cohort eligible for the EMBARK trial.
Sleep Breath
January 2025
Clinical Internal Medicine Department, Shanghai Health and Medical Center, Wuxi, 214065, People's Republic of China.
Background: Obstructive sleep apnea has been associated with various urinary system diseases, including prostatic hyperplasia and nocturia. Recently, it has been linked to prostate cancer. This study investigated the relationship between the apnea hypopnea index, prostate-specific antigen (PSA) levels, and changes in PSA.
View Article and Find Full Text PDFCancer Immunol Immunother
January 2025
Biobizkaia Health Research Institute, 48903, Barakaldo, Spain.
Clear cell renal cell carcinoma (ccRCC) is one of the most challenging neoplasms because of its phenotypic variability and intratumoral heterogeneity. Because of its variability, ccRCC is a good test bench for the application of new technological approaches to unveiling its intricacies. Multiplex immunofluorescence (mIF) is an emerging method that enables the simultaneous and detailed assessment of tumor and stromal cell subpopulations in a single tissue section.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Texas A&M Health Science Center, Bryan, TX, USA.
Background: Traumatic brain injury (TBI) is a serious societal concern and is considered a major risk factor for the development of Alzheimer's disease (AD) and related dementias. Identifying shared pathological mediators that contribute to the progression of AD following TBI may allow therapeutic targeting to reduce the likelihood of developing AD following TBI. Cerebrovascular dysfunction is present in both AD and TBI, and thrombin has been implicated as a mediator of cerebrovascular dysfunction and inflammation.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Michigan State University, Grand Rapids, MI, USA.
Background: A recent study of familial Alzheimer's disease identified a mutation in the RELN gene that appeared to delay the onset of dementia. It was hypothesized that this RELN-COLBOS variant protected against dementia by enhanced signaling at reelin receptors. We previously developed a secreted, bio-active reelin fragment (R36) and packaged it into AAV.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!